|
|
|
|
|
|
|
|
|
|
|
09.09.26 - 14:09
|
Proveris Scientific Appoints Daniel Tereau as President and Chief Executive Officer (Business Wire)
|
|
|
Veteran life sciences executive brings more than two decades of leadership in strategy, growth and corporate development to lead the next phase of Proveris' evolutionHUDSON, Mass.--(BUSINESS WIRE)--#CEOAppointment--Proveris Scientific, a leading provider of instrumentation and services that advance the science of aerosol and spray products and an independently managed portfolio company of Investindustrial Growth III Holdings S.à r.l. ("Investindustrial"), announces the appointment of Daniel Tereau as President and Chief Executive Officer, effective September 1, 2026.
Tereau brings more than two decades of executive leadership across life sciences, diagnostics, healthcare and technology, with a track record spanning growth strategy, mergers and acquisitions, commercialization and business transformation. He has held senior leadership roles at Revvity, Novartis Consumer Health, Thermo Fisher Scientific and GE Healthcare, where he led major acquisitions, portfolio transformation and commercial gr...
|
|
|
|
|
09.09.26 - 12:03
|
Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery (Business Wire)
|
|
|
Acquisition strengthens Revvity's position in human-relevant life sciences tools for next-generation GLP-1 and GPCR-targeting therapies for metabolic drug discovery
Combines HCD's human pancreatic beta cell models with Revvity's capabilities in cell analysis, detection, high-content screening and gene editing
Expands Revvity's ability to support customers across the research-to-clinic continuum, including emerging applications in clinical development and regenerative medicine
WALTHAM, Mass.--(BUSINESS WIRE)--#AI--Revvity, Inc. (NYSE: RVTY) today announced it has entered into a definitive agreement to acquire Human Cell Design (HCD), a France-based biotechnology company specializing in human cell models and preclinical research solutions for diabetes, obesity and other metabolic diseases. The acquisition is expected to add HCD's human pancreatic beta cell models to Revvity's Life Sciences portfolio, supporting drug discovery, screening and preclinical research, including applications in GLP-1 and oth...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
04.08.26 - 13:54
|
Revvity Lifts Annual Earnings, Revenue Outlook (AFX)
|
|
|
WASHINGTON (dpa-AFX) - Revvity, Inc. (RVTY), a life sciences and diagnostics company, on Tuesday revised up its annual guidance.For fiscal 2026, the company now expects pro forma adjusted earnings......
|
|
|
04.08.26 - 12:49
|
Revvity, Inc. Bottom Line Drops In Q2 (AFX)
|
|
|
WASHINGTON (dpa-AFX) - Revvity, Inc. (RVTY) revealed a profit for second quarter that Drops, from the same period last yearThe company's bottom line totaled $51.820 million, or $0.47 per share. Th......
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
